This story was originally posted on Feb. 28.

CombiMatrix, a publicly traded molecular diagnostics laboratory that specializes in microarray-based prenatal testing, does not see noninvasive, next-generation sequencing-based prenatal tests as a threat to its business, according to its new CEO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.